Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels-Reference-Cited by-同舟云学术

Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels

Published:2016-10-10 Issue:11 Volume:126 Page:4319-4330
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Rué Laura,Bañez-Coronel Mónica,Creus-Muncunill Jordi,Giralt Albert,Alcalá-Vida Rafael,Mentxaka Gartze,Kagerbauer Birgit,Zomeño-Abellán M. Teresa,Aranda Zeus,Venturi Veronica,Pérez-Navarro Esther,Estivill Xavier,Martí Eulàlia

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference58 articles.

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

2. Normal huntingtin function: an alternative approach to Huntington's disease

3. Polyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?

4. Huntington's disease: underlying molecular mechanisms and emerging concepts

5. CAG expansion induces nucleolar stress in polyglutamine diseases

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Latest advances on new promising molecular-based therapeutic approaches for Huntington’s disease;Journal of Translational Internal Medicine;2024-04-01

2. Nuclear pore dysfunction and disease: a complex opportunity;Nucleus;2024-02-21

3. A cyclic pyrrole-imidazole polyamide reduces pathogenic RNA in CAG/CTG triplet repeat neurological disease models;Journal of Clinical Investigation;2023-11-15

4. m6A RNA modification of mHttintron 1 regulates the generation ofHtt1ain Huntington’s Disease;2023-11-10

5. Exploring the Potential Therapeutic Approach Using Ginsenosides for the Management of Neurodegenerative Disorders;Molecular Biotechnology;2023-06-18